860 related articles for article (PubMed ID: 17439977)
1. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the intralesional treatment with Chenopodium ambrosioides in the murine infection by Leishmania amazonensis.
Patrício FJ; Costa GC; Pereira PV; Aragão-Filho WC; Sousa SM; Frazão JB; Pereira WS; Maciel MC; Silva LA; Amaral FM; Rebêlo JM; Guerra RN; Ribeiro MN; Nascimento FR
J Ethnopharmacol; 2008 Jan; 115(2):313-9. PubMed ID: 18035510
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
4. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure.
Coutinho SG; Oliveira MP; Da-Cruz AM; De Luca PM; Mendonça SC; Bertho AL; Soong L; McMahon-Pratt D
Exp Parasitol; 1996 Nov; 84(2):144-55. PubMed ID: 8932764
[TBL] [Abstract][Full Text] [Related]
5. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
Zauli-Nascimento RC; Miguel DC; Yokoyama-Yasunaka JK; Pereira LI; Pelli de Oliveira MA; Ribeiro-Dias F; Dorta ML; Uliana SR
Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis.
Calvopina M; Barroso PA; Marco JD; Korenaga M; Cooper PJ; Nonaka S; Hashiguchi Y
Vaccine; 2006 Jul; 24(27-28):5645-52. PubMed ID: 16621179
[TBL] [Abstract][Full Text] [Related]
7. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F
Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
[TBL] [Abstract][Full Text] [Related]
9. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
[TBL] [Abstract][Full Text] [Related]
10. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody.
Nabors GS; Farrell JP
Am J Trop Med Hyg; 1995 Jul; 53(1):55-60. PubMed ID: 7625533
[TBL] [Abstract][Full Text] [Related]
11. The pentavalent antimonial therapy against experimental Leishmania amazonensis infection is more effective under the inhibition of the NF-κB pathway.
Macedo SR; de Figueiredo Nicolete LD; Ferreira Ados S; de Barros NB; Nicolete R
Int Immunopharmacol; 2015 Sep; 28(1):554-9. PubMed ID: 26218282
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
13. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
Demicheli C; Ochoa R; da Silva JB; Falcão CA; Rossi-Bergmann B; de Melo AL; Sinisterra RD; Frézard F
Antimicrob Agents Chemother; 2004 Jan; 48(1):100-3. PubMed ID: 14693525
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
Asilian A; Sadeghinia A; Faghihi G; Momeni A
Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes.
Miguel DC; Yokoyama-Yasunaka JK; Andreoli WK; Mortara RA; Uliana SR
J Antimicrob Chemother; 2007 Sep; 60(3):526-34. PubMed ID: 17584801
[TBL] [Abstract][Full Text] [Related]
16. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
17. Allopurinol in the treatment of American cutaneous leishmaniasis.
Martinez S; Marr JJ
N Engl J Med; 1992 Mar; 326(11):741-4. PubMed ID: 1738379
[TBL] [Abstract][Full Text] [Related]
18. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.
Romero GA; de la Glória Orge Orge M; de Farias Guerra MV; Paes MG; de Oliveira Macêdo V; de Carvalho EM
Acta Trop; 2005 Jan; 93(1):49-56. PubMed ID: 15589797
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory effect of Canova medication on experimental Leishmania amazonensis infection.
Pereira WK; Lonardoni MV; Grespan R; Caparroz-Assef SM; Cuman RK; Bersani-Amado CA
J Infect; 2005 Aug; 51(2):157-64. PubMed ID: 16038768
[TBL] [Abstract][Full Text] [Related]
20. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis.
Stamm LM; Räisänen-Sokolowski A; Okano M; Russell ME; David JR; Satoskar AR
J Immunol; 1998 Dec; 161(11):6180-8. PubMed ID: 9834104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
